Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Cash (2018 - 2025)

Neurogene (NGNE) has disclosed Change in Cash for 5 consecutive years, with $12.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 127.46% year-over-year to $12.2 million, compared with a TTM value of $4.4 million through Sep 2025, up 105.15%, and an annual FY2024 reading of -$11.8 million, down 117.68% over the prior year.
  • Change in Cash was $12.2 million for Q3 2025 at Neurogene, up from -$12.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $70.0 million in Q4 2024 and bottomed at -$65.8 million in Q1 2025.